Risperidone (Risperdal): Clinical and Economic OutcomesError processing SSI file
A preliminary study, in which a total of 43 patients were included in this two-year, mirror-design study. The types of service utilization (inpatient, ER, outpatient), medication costs, and overall costs were measured in a 1-year period prior to and then after risperidone initiation. Clinical measures to document symptom improvement were done at medication initiation and at 6 months.
- 78% Reduction in inpatient utilization occurred after risperidone was initiated.
- 60% Reduction in acute ER utilization occurred after risperidone initiation.
- Improvement in symptoms of schizophrenia as measured by PANSS and negative subscale scores
- Overall mean costs savings of $262 per pt/month. (n=43) when all services included, even through medication itself is more expensive.